Quick Facts

• Addresses: Nausea and vomiting.
• Contexts of Use: May be used to help manage symptoms associated with chemotherapy, radiation therapy, or post-operative recovery.

Stopit is a medication utilized in the management of nausea and vomiting across a number of clinical situations. Its primary role involves providing relief from the discomfort and risks associated with these symptoms. The therapeutic application of Stopit includes assisting patients undergoing treatment that may induce sickness, such as chemotherapy or radiation exposure, which are commonly associated with nausea and emesis.

This medication may also be provided to support recovery following surgical procedures, where it helps address post-operative nausea and vomiting (PONV). The goal of treatment with Stopit is to maintain patient comfort and support recovery by managing these symptoms. Use of this agent should always follow the guidance of a qualified healthcare professional.

Regulatory References

1. NIH MedlinePlus guidance

Eligibility Map: Who can and cannot use Stopit — official regulatory information

Eligibility scope

Scope	Statement
Populations for whom use is allowed	Adults and adolescents ge 12 years for acute diarrhea. Children ge 2 years for acute, non-specific diarrhea, under conditional use.
Populations for whom use is not recommended	Nursing mothers (due to excretion in breast milk).
Populations for whom use is contraindicated	Pediatric patients less than 2 years of age; individuals with known hypersensitivity.
Age-related eligibility rules	Use is prohibited for children under 2 years. Special caution is advised for young children ge 2 years due to variable response.
Condition-specific eligibility rules	Contraindicated in patients with acute dysentery, acute ulcerative colitis, bacterial enterocolitis, pseudomembranous colitis, and abdominal pain without diarrhea.
Pregnancy and lactation eligibility status	Pregnancy Category C (FDA): Use only if the potential benefit justifies the potential risk to the fetus. Lactation: Not recommended.
Eligibility-related restrictions	Use with caution is required for patients with hepatic impairment. No dose adjustment is specified for renal impairment.

---

Eligibility classifications (high-level)

Classification	Statement
Eligibility severity classification	Contraindicated (absolute prohibition); Not Recommended (avoidance); Use with Caution (conditional use).
Regulatory basis	Based on FDA Label and EMA/SmPC product information.
Eligibility-context constraints	Must not be used when inhibition of peristalsis is to be avoided due to the risk of ileus or toxic megacolon.

---

Resulting eligibility structure

Official eligibility statements:

• Contraindicated in children under 2 years and in patients with known hypersensitivity.
• Prohibited in conditions where bowel inhibition is unsafe (e.g., acute dysentery, ulcerative colitis, certain bacterial enterocolitis).
• Use requires caution in patients with hepatic impairment and individuals with risk factors for QT prolongation.

Connection to the overall eligibility profile Official regulatory documents permit the use of Stopit primarily for adults and adolescents and prohibit its use in infants and patients with specified infectious or inflammatory bowel conditions. Eligibility is limited by the need for special caution when hepatic function is compromised and is not recommended during lactation, strictly defining the populations who can or cannot use the medicine.

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Stopit (Loperamide hydrochloride) around pharmacokinetic and pharmacodynamic constraints.

Interaction Scope

Detail	Official Regulatory Information
Medicinal product categories with documented interactions	Agents known to prolong the QT interval. P-glycoprotein (P-gp) inhibitors. CYP3A4 and CYP2C8 inhibitors.
Specific interacting medicines (if explicitly listed)	Quinidine, Ritonavir, Itraconazole, Ketoconazole, Gemfibrozil, and Saquinavir.
Interaction-related restrictions	Co-administration is contraindicated with medicinal products and herbal products that are known to prolong the QT interval due to the increased risk of serious cardiac events.

---

Official Interaction Statements

• Co-administration with CYP3A4 and CYP2C8 inhibitors (e.g., itraconazole, gemfibrozil) increases loperamide plasma concentrations.
• Co-administration with P-glycoprotein inhibitors (e.g., quinidine, ritonavir) resulted in a two- to three-fold increase in loperamide plasma levels.
• Loperamide reduces the exposure of other co-administered drugs that are P-gp substrates, such as saquinavir.
• Use in patients with hepatic impairment should be cautious as systemic exposure may be increased due to reduced first-pass metabolism.

---

The regulatory profile mandates the absolute prohibition of co-use with QT-prolonging agents based on pharmacodynamic risk. Separately, the profile details pharmacokinetic changes where inhibition of P-gp or the metabolic enzymes CYP3A4/CYP2C8 is officially documented to increase loperamide exposure.

The action of loperamide is defined by its molecular and cellular effects on the regulatory pathways governing intestinal motility and fluid transport. Its activity is highly specific and does not involve the central nervous system (CNS).

---

Modulating Intestinal Motility via mu-Opioid Receptors

The drug functions as an agonist by binding to specific mu-opioid receptors located on the nerve cells (enteric neurons) in the intestinal wall. This binding inhibits the release of excitatory neurotransmitters like Acetylcholine (ACh). The resulting molecular cascade decreases the force and frequency of intestinal smooth muscle contractions (peristalsis). The physiological outcome of this action is an increase in the transit time of contents through the gut.

---

Regulating Fluid and Electrolyte Transport

In addition to slowing gut movement, the mu-receptor activation mechanism directly influences the intestinal lining, or epithelium. This mechanism supports the enhancement of water and electrolyte reabsorption from the intestinal lumen back into the body, while simultaneously decreasing fluid secretion into the gut. This dual effect alters the net fluid balance in the digestive system, resulting in modified physiological regulation of fluid exchange.

---

Ensuring Peripheral Action Specificity

This mechanism is characterized by its constraint to the periphery. The drug is actively prevented from reaching the CNS by the P-glycoprotein (P-gp) efflux pump, which transports Loperamide out of the brain at the blood-brain barrier. This transporter mechanism results in the drug's effect being confined to the anti-motility and anti-secretory physiological responses within the intestine.

How to Use Stopit

Stopit, which contains loperamide hydrochloride, is administered exclusively by the oral route. The standard dosing regimen for acute use is based on an event-driven schedule, beginning with a specific starting dose followed by smaller, subsequent doses. For adults experiencing acute, self-managed diarrhea, the treatment begins with an initial dose of 4 milligrams (mg) (two 2 mg units). Following the initial dose, 2 mg is taken after each subsequent unformed stool.

The frequency of administration is not fixed by time but is instead reactionary. The total daily amount must not exceed the specified maximum daily dose, which is typically limited to 8 mg for non-prescription use and up to 16 mg when used under professional guidance. Administration for acute relief is generally limited to a 48-hour duration for self-medication protocols.

It is important that this medication is used in conjunction with appropriate fluid and electrolyte replacement throughout the administration period. The medication may be taken with or without food. Specific administration rules apply to age groups: the drug is contraindicated for use in children under the age of two years, and dosing for children between 2 and 12 years requires calculation using age- or weight-based tables. No formal dose adjustments are specified for individuals with renal impairment.

Research evidence / Overview of Studies for Stopit (Loperamide)

Evidence for Use in Acute, Non-Specific Diarrhea

Research exploring the evaluation of loperamide use in acute, sudden-onset diarrhea primarily relies on short-term Randomized Controlled Trials (RCTs) and systematic reviews. These studies examine patient populations, including adults and children aged 2 years and older. The outcomes related to physical discomfort that were studied often included measuring the duration of the diarrhea episode and the time until the last unformed stool (TTLUS).

Studies described how symptoms evolved in the observed populations, noting patterns related to the time measured until the last unformed stool. Research evaluated changes measured during the study period for outcomes such as stool frequency. Findings from these multiple RCTs contribute to the broader evidence landscape that explored short-term symptom changes.

However, research so far indicates that long-term outcomes following multiple brief episodes of acute diarrhea are not fully established by existing study designs. Data are also still emerging, and certainty remains low regarding the evaluation in specific vulnerable groups, such as children younger than 3 years or individuals with concurrent severe systemic illness.

Evidence for Use in Traveler's Diarrhea

Research for traveler's diarrhea relies on Randomized Clinical Trials (RCTs), where loperamide was examined alone or alongside different antibiotic treatments. These studies focused on examining adult travelers. Outcomes measured included the duration of the illness and the rate at which clinical cure, as defined by trial criteria, was achieved.

Research examined patterns observed when loperamide was combined with certain antibiotics versus when those agents were used alone. This evidence contributes to understanding symptom patterns in this context, particularly related to outcomes describing episodic or acute changes.

Despite these findings, research is limited concerning the selection of treatment when loperamide is used alongside antibiotics in the context of specific, highly virulent or resistant bacterial infections. The underlying causes of traveler's diarrhea vary, and research is ongoing to detail the outcomes for all possible pathogens.

Evidence in Specialized or Chronic Contexts

Loperamide was evaluated in clinical trials and long-term observational studies for its role in managing symptoms of chronic diarrhea associated with certain long-term conditions or for reducing output in patients with an ileostomy. The evidence base includes fewer large-scale, placebo-controlled RCTs, and there is significant variability in study design and populations. Research focuses exclusively on symptom control, providing limited insight into the impact on the underlying chronic disease progression itself.

Key Studies & References

1. Loperamide: Drug Information. Loperamide - Uses, Side Effects, and More.

Common questions about Stopit (FAQ)

---

Q: How quickly should I expect to notice a change after starting Stopit?

A: Official studies evaluating the medication's effects often measure the Time to Last Unformed Stool (TTLUS), which is the time it takes for symptoms to stop. This focus supports the drug's role as a symptomatic relief agent for acute episodes, which may be felt quickly.

---

Q: Does Stopit work immediately or does it take a while to build up?

A: The active ingredient's mechanism involves a direct action in the gut wall to manage acute symptoms. Regulatory information indicates that the medicine is not typically expected to require a prolonged buildup period for its effects to begin.

---

Q: What happens if I miss a use of Stopit?

A: Since the medication is used on an event-driven schedule, meaning it is taken after an unformed stool, official instructions do not typically include a specific 'missed dose' protocol. Information provided in regulatory documents suggests continuing with the next required use as directed by the event-driven schedule.

---

Q: Does Stopit affect my ability to drive or operate machinery?

A: The official label warns that conditions associated with diarrhea, as well as side effects such as somnolence (drowsiness) or dizziness, may occur. Official guidance highlights that if these side effects occur, caution is advised regarding activities such as driving or operating machinery.

---

Q: Is it okay to drink alcohol while I am using Stopit?

A: Official warnings caution against using the medication with other substances that may cause drowsiness or dizziness. Official guidance emphasizes that combining the medication with alcohol could potentially increase the risk of these side effects.

---

Q: Will Stopit interfere with my birth control pills?

A: Regulatory documentation, including the official label, is reviewed for drug-to-drug interactions. No specific interaction with oral contraceptives has been listed or documented in the official regulatory information for the active ingredient in Stopit.

---

Q: Is Stopit a controlled substance or habit-forming?

A: The active ingredient is a synthetic opioid derivative, but official documents note it is not classified as a controlled substance by regulatory agencies. Furthermore, the label describes a low potential for physical dependence when the medication is used strictly according to the approved duration and use conditions.

---

Q: What happens if I stop using Stopit suddenly?

A: Because the medicine is typically used for acute, self-limiting episodes, there is no specific protocol or taper required for cessation. Official documents do not list any expected withdrawal effects upon immediate discontinuation of use as directed.

---

Q: How is Stopit removed from the body?

A: The drug is eliminated from the body primarily through the biliary system and then excreted via feces, following extensive metabolism in the liver. This process is detailed in regulatory pharmacokinetic information.

---

Q: How long do the effects of Stopit last after the last use?

A: Official documents describe the elimination half-life of the active ingredient as approximately 11 hours. The half-life refers to the time it takes for half of the drug to be removed from the bloodstream.

---

Q: Is there a generic version of Stopit available?

A: The active ingredient in Stopit is loperamide hydrochloride. This ingredient is widely available in generic formulations, in addition to the brand name products, as confirmed by national regulatory databases.

---

Q: What does it mean if Stopit has a Black Box Warning?

A: Stopit's official FDA label does not include a Black Box Warning for use within the recommended doses. However, the label contains a specific Warning section regarding the risk of serious cardiac events when the medication is used in doses exceeding the maximum recommended amount.

---

Q: Does Stopit interact with grapefruit or grapefruit juice?

A: Official documents warn that co-administration with strong CYP3A4 inhibitors increases the plasma concentrations of the active ingredient. Since grapefruit juice is a known CYP3A4 inhibitor, an interaction is expected based on this documented mechanism.

---

Q: Is Stopit considered a new medication?

A: The active ingredient, loperamide, was first approved and introduced decades ago, starting in the 1970s. Given this history, the medication is widely considered a well-established treatment.

---

Q: Is it possible to develop a tolerance to Stopit?

A: Official regulatory documents for the medication specifically address the potential for dependence and tolerance. The drug has a low potential for physical dependence or tolerance when it is used strictly according to the approved use conditions and limited duration.

---

Q: What information is included in the Patient Information Leaflet for Stopit?

A: The Patient Information Leaflet (PIL) is a regulatory document required for the medication. It summarizes essential facts, including how the medicine works, how to use it, warnings, side effects, and who should not take it, based on official prescribing information.

---

Q: Does Stopit have any serious interactions with common vitamins or supplements?

A: Official regulatory documents list interactions with specific herbal products and drugs that affect metabolic enzymes. However, no specific interaction with common essential vitamins (such as B vitamins, or Vitamin C) is documented in the prescribing information.

---

Q: Are there any dietary restrictions I should know about when using Stopit?

A: The medication may generally be taken with or without food. Official documents do warn against co-administration with certain products, such as grapefruit juice, because they may increase the drug's systemic exposure.

---

Q: Why do some people say Stopit didn't work for them?

A: Official documents and research suggest that individual response to antidiarrheal agents can vary among patients. Furthermore, official documents state that the medication is contraindicated for use in certain infectious diarrheas or inflammatory conditions, where treatment benefit may not be observed.

---

Q: How do I know if I am eligible to use Stopit?

A: Eligibility is defined by official regulatory criteria, which are based on patient demographics and pre-existing conditions. These criteria include specific age requirements (prohibited under 2 years) and contraindications related to certain underlying gastrointestinal conditions.

---

Q: Why do official documents emphasize talking to a doctor about my medical history before using Stopit?

A: Official documents require caution for use in patients with hepatic impairment (liver problems) and those with risk factors for QT prolongation (a type of heart rhythm concern). These warnings make a review of the patient's full medical history necessary for proper evaluation.

---

Q: Does the age of the user affect how Stopit works?

A: The mechanism of action in the gut is described as being the same across all approved populations. However, the regulatory documentation includes age-based dosing and specific safety cautions, particularly for younger children.

The official regulatory guidelines for Stopit (loperamide) specify precise conditions for storage and disposal to ensure product integrity and public safety.

Storage Conditions

Requirement	Specific Condition
Temperature	Store at Controlled Room Temperature: 20 C to 25 C (68 F to 77 F), avoiding temperatures above 30 C and excessive heat.
Protection	Must be protected from light and moisture (avoid storing in humid areas like bathrooms).
Packaging	Keep in a tight, light-resistant container. Do not use if the original blister unit is broken or torn.
Child Safety	Keep the medication strictly out of the reach and sight of children.

Disposal Instructions

Unused or expired Stopit should ideally be discarded via a drug take-back program. If this option is unavailable, the medicine must be mixed with an undesirable substance, sealed in a container, and thrown into the household trash. It is explicitly stated that this medication must not be flushed down a toilet or sink.